Approximately 9 weeks until the next quarterly briefing to be...

Approximately 9 weeks until the next quarterly briefing to be held at the end of October. TK advised that we'll then be advised of Q3's number of tests and cashflow for both platforms; ResAppDx and SleepCheck.

TK's final comments (before Q&A) at the last quarterly briefing were that further Aus ResAppDx expansion, UK ResAppDx expansion, and SleepCheck's marketing campaign were to be the focus in Q3.

Once one UK Telehealth company signs up, others will need to follow due to the risk of loss of competitive advantage.

We're also expecting handheld and wearable device CE approval, and ResAppDx FDA resubmission in Q3.

We're on the cusp of greatness. I strongly believe that the current frustration will be well worth it by Christmas.

DYOR, GLTAH, IMO only